“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis. MorphoSys AG (FSE: MOR NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023. PLANEGG/ MUNICH, Germany-(BUSINESS WIRE). – € 642.2 million in cash and other financial assets as of September 30, 2023Ĭonference call and webcast (in English) tomorrow, November 16, 2023, at 2:00 pm CET (1:00 pm GMT/8:00 am ET) FDA granted Fast Track designation for tulmimetostat in ARID1A-mutated endometrial cancer net product sales of US$ 23.4 million (€ 21.5 million) for the third quarter of 2023 – Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |